Holen Sie sich die Stockscreener-App
190.85
0.35%
0.67
Vorhandelsmarkt:
191.00
0.15
+0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$190.18
Offen:
$188.81
24-Stunden-Volumen:
693.14K
Relative Volume:
0.72
Marktkapitalisierung:
$21.13B
Einnahmen:
$11.28B
Nettoeinkommen (Verlust:
$1.07B
KGV:
21.05
EPS:
9.0657
Netto-Cashflow:
$1.33B
1W Leistung:
+0.91%
1M Leistung:
-1.07%
6M Leistung:
+1.74%
1J Leistung:
+9.38%
1-Tages-Spanne:
$187.51
$191.11
1-Wochen-Bereich:
$186.23
$192.30
52-Wochen-Spanne:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
190.85 | 21.05B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
446.03 | 170.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
165.99 | 117.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.68 | 42.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
334.93 | 34.57B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.74 | 31.91B | 7.07B | 1.29B | 993.00M | 4.5355 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics (NYSE: DGX) sells $500M in 5.000% senior notes due 2036 - Stock Titan
Bullish Quarterly Results: 3 Companies Raising Guidance - TradingView
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term - Yahoo Finance
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
DGX6380050 Bond Analysis — Key Metrics - TradingView
Quest Diagnostics Incorporated $DGX Shares Sold by Keybank National Association OH - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Acquired by Davis Selected Advisers - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Holdings Increased by Artemis Investment Management LLP - MarketBeat
Quest Diagnostics | 8-K: Current report - Moomoo
Quest Diagnostics Incorporated (NYSE:DGX) Short Interest Update - MarketBeat
Quest Diagnostics prices $500M 5.00% senior notes due 2036 to fund general purposes - TradingView
[8-K] QUEST DIAGNOSTICS INC Reports Material Event - Stock Titan
Quest Diagnostics Incorporated $DGX Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by Danica Pension Livsforsikringsaktieselskab - MarketBeat
Quest Diagnostics | SCHEDULE 13G: Others - Moomoo
Vanguard reports 8.27M Quest Diagnostics shares (NYSE: DGX) stake - Stock Titan
Quest Diagnostics Inc (DGX) Stock Price & 30 Year Financial Data - GuruFocus
Quest Diagnostics Incorporated $DGX Shares Purchased by UBS Group AG - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Purchased by Vanguard Group Inc. - MarketBeat
Valmont Industries posts upbeat Q1 results, joins UnitedHealth Group, Quest Diagnostics and other big stocks moving higher on Tuesday - MSN
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DGX6380050 Bond Price and Chart — FINRA:DGX6380050 - TradingView
Vanguard reports 6.10M-share stake in Quest Diagnostics (DGX) — 5.54% - Stock Titan
Quest Diagnostics (DGX) sells $500M 5.00% senior notes due 2036 at 98.751% - Stock Titan
Quest Diagnostics Debt Raise And ctDNA Alliance Spark Valuation Questions - Yahoo Finance
JPMorgan Mid Cap Value Fund's Quest Diagnostics Inc(DGX) Holding History - GuruFocus
BlackRock Systematic Multi-Strategy Fund's Quest Diagnostics Inc(DGX) Holding History - GuruFocus
Quest Diagnostics Prices $500 Million of Senior Notes - GuruFocus
Smart Money is Buying Quest Diagnostics Inc. (DGX) - The Acquirer's Multiple
Quest Diagnostics Inc (DGX) Stock Price, Trades & News - GuruFocus
Quest Diagnostics Incorporated (DGX) stock price, news, quote and history - Yahoo Finance Australia
Quest Diagnostics prices $500 million senior notes offering By Investing.com - Investing.com Canada
Quest Diagnostics Inc files for senior notes, size not disclosed - marketscreener.com
Quest Diagnostics (DGX) launches senior note offering; may repay $500M 2026 notes - Stock Titan
Quest Diagnostics prices $500M debt deal ahead of June note maturity - Stock Titan
Advisors Capital Management LLC Buys 16,194 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Evercore ISI Group Maintains Quest Diagnostics (DGX) In-Line Recommendation - MSN
Quest Diagnostics Incorporated $DGX Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity - Stock Titan
Quest Diagnostics (DGX) SVP reports 49-share dividend reinvestment - Stock Titan
Quest Diagnostics (NYSE: DGX) director acquires shares through dividend reinvestment - Stock Titan
Dividend plan boosts Quest Diagnostics (NYSE: DGX) director stake - Stock Titan
Quest Diagnostics (DGX) director boosts holdings with small dividend reinvestment - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP reports small 39-share acquisition - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP adds 37 shares through dividend reinvestment - Stock Titan
Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely (NYSE:DGX) - Seeking Alpha
Copeland Capital Management LLC Cuts Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Holdings Decreased by Cwm LLC - MarketBeat
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):